SST and plasma cell myeloma: Currently, there are only two PDCs that have been granted FDA approval in the management of malignancies; Lu 177 dotatate, a radiolabeled somatostatin analog for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and Melflufen, used in the treatment of patients with relapsed or refractory multiple myeloma but which was later withdrawn from the market [156].